WARNING: HEMATOLOGIC TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, and EXACERBATIONS OF HEPATITIS B Zidovudine, a component of COMBIVIR (lamivudine and zidovudine) tablets, has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV ‑ 1) disease [see Warnings and Precautions (5.1)]. Prolonged use of zidovudine has been associated with symptomatic myopathy [see Warnings and Precautions (5.2)].
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, including lamivudine and zidovudine (components of COMBIVIR). Discontinue COMBIVIR if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur [see Warnings and Precautions (5.3)].
Severe acute exacerbations of hepatitis B have been reported in patients who are co ‑ infected with hepatitis B virus (HBV) and HIV ‑ 1 and have discontinued lamivudine, which is one component of COMBIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue COMBIVIR and are co ‑ infected with HIV ‑ 1 and HBV.
If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.4)]. WARNING: HEMATOLOGIC TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, and EXACERBATIONS OF HEPATITIS B See full prescribing information for complete boxed warning
- Hematologic toxicity, including neutropenia and anemia, has been associated with the use of zidovudine, a component of COMBIVIR. (5.1)
- Symptomatic myopathy associated with prolonged use of zidovudine. (5.2)
- Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including lamivudine and zidovudine (components of COMBIVIR). Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur. (5.3)
- Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV ‑ 1) and have discontinued lamivudine, a component of COMBIVIR. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment. (5.4)
Use: Labeled indications
- COMBIVIR, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE COMBIVIR, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. COMBIVIR, a combination of 2 nucleoside analogue reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. (1)
Contraindications
4 CONTRAINDICATIONS COMBIVIR is contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine. COMBIVIR is contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine. (4)
US FDA labelDosing: Adult
- • Adults and Adolescents weighing greater than or equal to 30 kg: 1 tablet orally twice daily. (2.1)
- • Pediatrics weighing greater than or equal to 30 kg: 1 tablet orally twice daily. (2.2)
- • Because COMBIVIR is a fixed‑dose tablet and cannot be dose adjusted, COMBIVIR is not recommended in patients requiring dosage adjustment or with hepatic impairment or experiencing dose‑limiting adverse reactions. (2.3, 4)
2.1 Recommended Dosage for Adults and Adolescents
2.1 Recommended Dosage for Adults and Adolescents The recommended dosage of COMBIVIR in HIV‑1‑infected adults and adolescents weighing greater than or equal to 30 kg is 1 tablet (containing 150 mg of lamivudine and 300 mg of zidovudine) taken orally twice daily.
2.2 Recommended Dosage for Pediatric Patients
2.2 Recommended Dosage for Pediatric Patients The recommended dosage of scored COMBIVIR tablets for pediatric patients who weigh greater than or equal to 30 kg and for whom a solid oral dosage form is appropriate is 1 tablet administered orally twice daily. Before prescribing COMBIVIR tablets, children should be assessed for the ability to swallow tablets.
If a child is unable to reliably swallow a COMBIVIR tablet, the liquid oral formulations should be prescribed: EPIVIR (lamivudine) oral solution and RETROVIR (zidovudine) syrup.
2.3 Not Recommended Due to Lack of Dosage Adjustment Because
2.3 Not Recommended Due to Lack of Dosage Adjustment Because COMBIVIR is a fixed‑dose tablet and cannot be dose adjusted, COMBIVIR is not recommended for:
- pediatric patients weighing less than 30 kg [see Use in Specific Populations (8.4)].
- patients with creatinine clearance less than 50 mL per minute [see Use in Specific Populations (8.6)].
- patients with hepatic impairment [see Use in Specific Populations (8.7)].
- patients experiencing dose‑limiting adverse reactions. Liquid and solid oral formulations of the individual components of COMBIVIR are available for these populations.
Dosing: Altered kidney function
8.6 Patients with Impaired Renal Function COMBIVIR is not recommended for patients with creatinine clearance less than 50 mL per min because COMBIVIR is a fixed‑dose combination and the dosage of the individual components cannot be adjusted. If a dose reduction of the lamivudine or zidovudine components of COMBIVIR is required for patients with renal impairment then the individual components should be used [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].
Patients with Renal Impairment: COMBIVIR: The effect of renal impairment on the combination of lamivudine and zidovudine has not been evaluated (see the U.S. prescribing information for the individual lamivudine and zidovudine components).
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Patients with Impaired Hepatic Function COMBIVIR is a fixed‑dose combination and the dosage of the individual components cannot be adjusted. Zidovudine is primarily eliminated by hepatic metabolism and zidovudine concentrations are increased in patients with impaired hepatic function, which may increase the risk of hematologic toxicity. Frequent monitoring of hematologic toxicities is advised.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use COMBIVIR is not recommended for use in pediatric patients who weigh less than 30 kg because it is a fixed‑dose combination tablet that cannot be adjusted for this patient population [see Dosage and Administration (2.2)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical trials of COMBIVIR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, caution should be exercised in the administration of COMBIVIR in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Clinical Pharmacology (12.3)].
Dosage forms
Philippines
- Film-coated tablet: 150 mg/300 mg
Registered products in the Philippines
4 products registered with the Food and Drug Administration (FDA) Philippines list Lamivudine + Zidovudine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products4
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
DuovirLamivudine + Zidovudine | 150mg / 300 mg Film-Coated TabletWhite opaque HDPE bottle with white opaque non-child-resistant screw cap x 60 tablets (Box of 60 tablets) | Rx | Cipla Limited - Goa (Unit VII)India | Phil Pharmawealth, Inc. | DR-XY47458 | Oct 13, 2031 | |
LavuzidLamivudine + Zidovudine | 150mg/300mg Film Coated TabletWhite opaque HDPE bottle with white opaque PP screw cap x 60 tablets (Box of 60 tablets) | Rx | Hetero Labs Limited (Unit III)India | Camber Pharmaceuticals, Inc. | DR-XY47997 | May 5, 2027 | |
NoneLamivudine + Zidovudine | 150 mg/ 300 mg Film-Coated TabletHDPE Bottle with child resistant closure and screw cap with induction seal liner x 60’s (Box of 1’s) | Rx | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DR-XY46999 | Feb 7, 2037 | |
ZidolamLamivudine + Zidovudine | 150 mg / 300 mg Film-Coated TabletWhite opaque HDPE bottle with white opaque continuous threading PP cap x 60 tablets Box of 60 tablets | Rx | Hetero Labs LimitedIndia | S.M.H.P. Marketing & Consultancy | DR-XY45902 | May 23, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS COMBIVIR tablets contain 150 mg of lamivudine and 300 mg of zidovudine. The tablets are white, scored, film‑coated, modified capsule‑shaped tablets, debossed on both tablet faces, such that when broken in half, the full “GX FC3” code is present on both halves of the tablet (“GX” on one face and “FC3” on the opposite face of the tablet). Tablets: Scored 150 mg lamivudine and 300 mg zidovudine (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- • Hepatic decompensation, some fatal, has occurred in HIV‑1/HCV co‑infected patients receiving combination antiretroviral therapy and interferon alfa with/without ribavirin. Discontinue COMBIVIR as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. (5.5)
- • Exacerbation of anemia has been reported in HIV‑1/HCV co‑infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and zidovudine is not advised. (5.5)
- • Pancreatitis: Use with caution in patients with a history of pancreatitis or other significant risk factors for pancreatitis. Discontinue treatment as clinically appropriate. (5.6)
- • Immune reconstitution syndrome and lipoatrophy have been reported in patients treated with combination antiretroviral therapy. (5.7, 5.8)
5.1 Hematologic Toxicity/Bone Marrow Suppression
5.1 Hematologic Toxicity/Bone Marrow Suppression Zidovudine, a component of COMBIVIR, has been associated with hematologic toxicity including neutropenia and anemia, particularly in patients with advanced HIV‑1 disease. COMBIVIR should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000 cells per mm 3 or hemoglobin less than 9.5 grams per dL [see Adverse Reactions (6.1)].
Frequent blood counts are strongly recommended in patients with advanced HIV‑1 disease who are treated with COMBIVIR. Periodic blood counts are recommended for other HIV‑1‑infected patients. If anemia or neutropenia develops, dosage interruption may be needed.
5.2 Myopathy
5.2 Myopathy Myopathy and myositis, with pathological changes similar to that produced by HIV‑1 disease, have been associated with prolonged use of zidovudine, and therefore may occur with therapy with COMBIVIR.
5.3 Lactic Acidosis and Severe Hepatomegaly with Steatosis
5.3 Lactic Acidosis and Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, including lamivudine and zidovudine (components of COMBIVIR). A majority of these cases have been in women. Female sex and obesity may be risk factors for the development of lactic acidosis and severe hepatomegaly with steatosis in patients treated with antiretroviral nucleoside analogues.
See full prescribing information for EPIVIR (lamivudine) and RETROVIR (zidovudine). Treatment with COMBIVIR should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity, which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations.
5.4 Patients with Hepatitis B Virus Co-infection Posttreatment Exacerbations
5.4 Patients with Hepatitis B Virus Co-infection Posttreatment Exacerbations of Hepatitis Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of lamivudine. See full prescribing information for EPIVIR (lamivudine). Patients should be closely monitored with both clinical and laboratory follow‑up for at least several months after stopping treatment.
Emergence of Lamivudine ‑ Resistant HBV Safety and efficacy of lamivudine have not been established for treatment of chronic hepatitis B in subjects dually infected with HIV-1 and HBV. Emergence of hepatitis B virus variants associated with resistance to lamivudine has been reported in HIV–1-infected subjects who have received lamivudine‑containing antiretroviral regimens in the presence of concurrent infection with hepatitis B virus.
See full prescribing information for EPIVIR (lamivudine).
5.5 Use with Interferon- and Ribavirin
5.5 Use with Interferon- and Ribavirin–Based Regimens Patients receiving interferon alfa with or without ribavirin and COMBIVIR should be closely monitored for treatment‑associated toxicities, especially hepatic decompensation, neutropenia, and anemia. See full prescribing information for RETROVIR (zidovudine). Discontinuation of COMBIVIR should be considered as medically appropriate.
Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh greater than 6) (see full prescribing information for interferon and ribavirin). Exacerbation of anemia has been reported in HIV–1/HCV co–infected patients receiving ribavirin and zidovudine.
Coadministration of ribavirin and COMBIVIR is not advised.
5.6 Pancreatitis
5.6 Pancreatitis COMBIVIR should be used with caution in patients with a history of pancreatitis or other significant risk factors for the development of pancreatitis. Treatment with COMBIVIR should be stopped immediately if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur [see Adverse Reactions (6.1)].
5.7 Immune Reconstitution Syndrome
5.7 Immune Reconstitution Syndrome Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including COMBIVIR. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.
Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.
5.8 Lipoatrophy
5.8 Lipoatrophy Treatment with zidovudine, a component of COMBIVIR, has been associated with loss of subcutaneous fat. The incidence and severity of lipoatrophy are related to cumulative exposure. This fat loss, which is most evident in the face, limbs, and buttocks, may be only partially reversible and improvement may take months to years after switching to a non-zidovudine-containing regimen.
Patients should be regularly assessed for signs of lipoatrophy during therapy with zidovudine-containing products, and if feasible, therapy should be switched to an alternative regimen if there is suspicion of lipoatrophy.
Drug interactions
- • Agents antagonistic with zidovudine: Concomitant use should be avoided. (7.1)
- • Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. (7.1)
- • Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations; when possible, avoid chronic coadministration. (7.2)
7.1 Zidovudine Agents Antagonistic
7.1 Zidovudine Agents Antagonistic with Zidovudine Concomitant use of zidovudine with the following drugs should be avoided since an antagonistic relationship has been demonstrated in vitro:
- Stavudine
- Doxorubicine
- Nucleoside analogues, e.g., ribavirin Hematologic/Bone Marrow Suppressive/Cytotoxic Agents Coadministration with the following drugs may increase the hematologic toxicity of zidovudine:
- Ganciclovir
- Interferon alfa
- Ribavirin
- Other bone marrow suppressive or cytotoxic agents
7.2 Lamivudine Sorbitol
7.2 Lamivudine Sorbitol Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitol-containing medicines with lamivudine-containing medicines [see Clinical Pharmacology (12.3)].
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Lamivudine concentrations were generally similar in maternal, neonatal, and umbilical cord serum samples.
Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery.
Adverse reactions
- The following adverse reactions are discussed in other sections of the labeling: • Hematologic toxicity, including neutropenia and anemia [see Boxed Warning, Warnings and Precautions (5.1)]. • Symptomatic myopathy [see Boxed Warning, Warnings and Precautions (5.2)]. • Lactic acidosis and severe hepatomegaly with steatosis [see Boxed Warning, Warnings and Precautions (5.3)]. • Exacerbations of hepatitis B [see Boxed Warning, Warnings and Precautions (5.4)]. • Hepatic decompensation in patients co-infected with HIV‑1 and hepatitis C [see Warnings and Precautions (5.5)]. • Exacerbation of anemia in HIV‑1/HCV co-infected patients receiving ribavirin and zidovudine [see Warnings and Precautions (5.5)]. • Pancreatitis [see Warnings and Precautions (5.6)]. • Immune reconstitution syndrome [see Warnings and Precautions (5.7)]. • Lipoatrophy [see Warnings and Precautions (5.8)]. • Most commonly reported adverse reactions (incidence greater than or equal to 15%) in clinical trials of combination lamivudine and zidovudine were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Lamivudine plus Zidovudine Administered as Separate Formulations In 4 randomized, controlled trials of EPIVIR 300 mg per day plus RETROVIR 600 mg per day, the following selected adverse reactions and laboratory abnormalities were observed (Tables 1 and 2).
Table 1. Selected Clinical Adverse Reactions (Greater than or Equal to 5% Frequency) in 4 Controlled Clinical Trials with EPIVIR 300 mg per Day and RETROVIR 600 mg per Day Adverse Reaction EPIVIR plus RETROVIR (n = 251) Body as a whole Headache 35% Malaise & fatigue 27% Fever or chills 10% Digestive Nausea 33% Diarrhea 18% Nausea & vomiting 13% Anorexia and/or decreased appetite 10% Abdominal pain 9% Abdominal cramps 6% Dyspepsia 5% Nervous system Neuropathy 12% Insomnia & other sleep disorders 11% Dizziness 10% Depressive disorders 9% Respiratory Nasal signs & symptoms 20% Cough 18% Skin Skin rashes 9% Musculoskeletal Musculoskeletal pain 12% Myalgia 8% Arthralgia 5% Pancreatitis was observed in 9 of the 2,613 adult subjects (0.3%) who received EPIVIR in controlled clinical trials [see Warnings and Precautions (5.6)].
Selected laboratory abnormalities observed during therapy are listed in Table 2. Table 2. Frequencies of Selected Laboratory Abnormalities among Adults in 4 Controlled Clinical Trials of EPIVIR 300 mg per Day plus RETROVIR 600 mg per Day a Test (Abnormal Level) EPIVIR plus RETROVIR % (n) Neutropenia (ANC <750/mm 3) 7.2% (237) Anemia (Hgb <8.0 g/dL) 2.9% (241) Thrombocytopenia (platelets <50,000/mm 3) 0.4% (240) ALT (>5.0 x ULN) 3.7% (241) AST (>5.0 x ULN) 1.7% (241) Bilirubin (>2.5 x ULN) 0.8% (241) Amylase (>2.0 x ULN) 4.2% (72) ULN = Upper limit of normal.
ANC = Absolute neutrophil count. n = Number of subjects assessed. a Frequencies of these laboratory abnormalities were higher in subjects with mild laboratory abnormalities at baseline.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postmarketing use. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a Whole Redistribution/accumulation of body fat [see Warnings and Precautions (5.8)].
Cardiovascular Cardiomyopathy. Endocrine and Metabolic Gynecomastia, hyperglycemia. Gastrointestinal Oral mucosal pigmentation, stomatitis. General Vasculitis, weakness. Hemic and Lymphatic Anemia, (including pure red cell aplasia and anemias progressing on therapy), lymphadenopathy, splenomegaly. Hepatic and Pancreatic Lactic acidosis and hepatic steatosis, pancreatitis, posttreatment exacerbations of hepatitis B [see Boxed Warning, Warnings and Precautions (5.3), (5.4), (5.6)].
Hypersensitivity Sensitization reactions (including anaphylaxis), urticaria. Musculoskeletal Muscle weakness, CPK elevation, rhabdomyolysis. Nervous Paresthesia, peripheral neuropathy, seizures. Respiratory Abnormal breath sounds/wheezing. Skin Alopecia, erythema multiforme, Stevens‑Johnson syndrome.
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction | EPIVIR plus RETROVIR(n = 251) |
| Body as a whole | |
| Headache | 35% |
| Malaise & fatigue | 27% |
| Fever or chills | 10% |
| Digestive | |
| Nausea | 33% |
| Diarrhea | 18% |
| Nausea & vomiting | 13% |
| Anorexia and/or decreased appetite | 10% |
| Abdominal pain | 9% |
| Abdominal cramps | 6% |
| Dyspepsia | 5% |
| Nervous system | |
| Neuropathy | 12% |
| Insomnia & other sleep disorders | 11% |
| Dizziness | 10% |
| Depressive disorders | 9% |
| Respiratory | |
| Nasal signs & symptoms | 20% |
| Cough | 18% |
| Skin | |
| Skin rashes | 9% |
| Musculoskeletal | |
| Musculoskeletal pain | 12% |
| Myalgia | 8% |
| Arthralgia | 5% |
| Test(Abnormal Level) | EPIVIR plus RETROVIR% (n) |
| Neutropenia (ANC <750/mm3) | 7.2% (237) |
| Anemia (Hgb <8.0 g/dL) | 2.9% (241) |
| Thrombocytopenia (platelets <50,000/mm3) | 0.4% (240) |
| ALT (>5.0 x ULN) | 3.7% (241) |
| AST (>5.0 x ULN) | 1.7% (241) |
| Bilirubin (>2.5 x ULN) | 0.8% (241) |
| Amylase (>2.0 x ULN) | 4.2% (72) |
| ULN = Upper limit of normal. | |
| ANC = Absolute neutrophil count. | |
| n = Number of subjects assessed. | |
| a Frequencies of these laboratory abnormalities were higher in subjects with mild laboratory abnormalities at baseline. | |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to COMBIVIR during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263. Risk Summary Available data from the APR show no difference in the overall risk of birth defects for lamivudine or zidovudine compared with the background rate for birth defects of 2.7% in the Metropolitan Atlanta Congenital Defects Program (MACDP) reference population (see Data).
The APR uses the MACDP as the U.S. reference population for birth defects in the general population. The MACDP evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks’ gestation. The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15% to 20%.
The background risk for major birth defects and miscarriage for the indicated population is unknown. Hyperlactatemia, which may be due to mitochondrial dysfunction, has been reported in infants with in utero exposure to zidovudine-containing products. These events were transient and asymptomatic in most cases. There have been few reports of developmental delay, seizures, and other neurological disease.
However, a causal relationship between these events and exposure to zidovudine-containing products in utero or peri-partum has not been established (see Data). In animal reproduction studies, oral administration of lamivudine to pregnant rabbits during organogenesis resulted in embryolethality at systemic exposure (AUC) similar to the recommended clinical dose; however, no adverse development effects were observed with oral administration of lamivudine to pregnant rats during organogenesis at plasma concentrations (C max) 35 times the recommended clinical dose.
Administration of oral zidovudine to female rats prior to mating and throughout gestation resulted in embryotoxicity at doses that produced systemic exposure (AUC) approximately 33 times higher than exposure at the recommended clinical dose. However, no embryotoxicity was observed after oral administration of zidovudine to pregnant rats during organogenesis at doses that produced systemic exposure (AUC) approximately 117 times higher than exposures at the recommended clinical dose.
Administration of oral zidovudine to pregnant rabbits during organogenesis resulted in embryotoxicity at doses that produced systemic exposure (AUC) approximately 108 times higher than exposure at the recommended clinical dose. However, no embryotoxicity was observed at doses that produced systemic exposure (AUC) approximately 23 times higher than exposures at the recommended clinical dose (see Data).
Data Human Data: Lamivudine: Based on prospective reports to the APR of over 11,000 exposures to lamivudine during pregnancy resulting in live births (including over 4,500 exposed in the first trimester), there was no difference between the overall risk of birth defects for lamivudine compared with the background birth defect rate of 2.7% in a U.S. reference population of the MACDP. The prevalence of birth defects in live births was 3.1% (95% CI: 2.6% to 3.6%) following first trimester exposure to lamivudine-containing regimens and 2.8% (95% CI: 2.5% to 3.3%) following second/third trimester exposure to lamivudine-containing regimens.
Lamivudine pharmacokinetics were studied in pregnant women during 2 clinical trials conducted in South Africa. The trial assessed pharmacokinetics in 16 women at 36 weeks’ gestation using 150 mg lamivudine twice daily with zidovudine, 10 women at 38 weeks’ gestation using 150 mg lamivudine twice daily with zidovudine, and 10 women at 38 weeks’ gestation using lamivudine 300 mg twice daily without other antiretrovirals.
These trials were not designed or powered to provide efficacy information. Lamivudine concentrations were generally similar in maternal, neonatal, and umbilical cord serum samples. In a subset of subjects, amniotic fluid specimens were collected following natural rupture of membranes and confirmed that lamivudine crosses the placenta in humans.
Based on limited data at delivery, median (range) amniotic fluid concentrations of lamivudine were 3.9 (1.2 to 12.8)–fold greater compared with paired maternal serum concentration (n = 8). Zidovudine: Based on prospective reports to the APR of over 13,000 exposures to zidovudine during pregnancy resulting in live births (including over 4,000 exposed in the first trimester), there was no difference between the overall risk of birth defects for zidovudine compared with the background birth defect rate of 2.7% in a U.S. reference population of the MACDP.
The prevalence of birth defects in live births was 3.2% (95% CI: 2.7% to 3.8%) following first trimester exposure to zidovudine-containing regimens and 2.8% (95% CI: 2.5% to 3.2%) following second/third trimester exposure to zidovudine-containing regimens. A randomized, double-blind, placebo-controlled trial was conducted in HIV–1-infected pregnant women to determine the utility of zidovudine for the prevention of maternal-fetal HIV-1 transmission.
Zidovudine treatment during pregnancy reduced the rate of maternal-fetal HIV-1 transmission from 24.9% for infants born to placebo-treated mothers to 7.8% for infants born to mothers treated with zidovudine. There were no differences in pregnancy-related adverse events between the treatment groups. Of the 363 neonates that were evaluated, congenital abnormalities occurred with similar frequency between neonates born to mothers who received zidovudine and neonates born to mothers who received placebo.
The observed abnormalities included problems in embryogenesis (prior to 14 weeks) or were recognized on ultrasound before or immediately after initiation of trial drug [see Clinical Studies (14.2)]. Zidovudine has been shown to cross the placenta and concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery [see Clinical Pharmacology (12.3)].
There have been reports of mild, transient elevations in serum lactate levels, which may be due to mitochondrial dysfunction, in neonates and infants exposed in utero or peri-partum to zidovudine-containing products. There have been few reports of developmental delay, seizures, and other neurological disease. However, a causal relationship between these events and exposure to zidovudine-containing products in utero or peri-partum has not been established.
The clinical relevance of transient elevations in serum lactate is unknown. Animal Data: Lamivudine: Lamivudine was administered orally to pregnant rats (at 90, 600, and 4,000 mg per kg per day) and rabbits (at 90, 300, and 1,000 mg per kg per day and at 15, 40, and 90 mg per kg per day) during organogenesis (on gestation Days 7 through 16 [rat] and 8 through 20 [rabbit]).
No evidence of fetal malformations due to lamivudine was observed in rats and rabbits at doses producing plasma concentrations (C max) approximately 35 times higher than human exposure at the recommended daily dose. Evidence of early embryolethality was seen in the rabbit at system exposures (AUC) similar to those observed in humans, but there was no indication of this effect in the rat at plasma concentrations (C max) 35 times higher than human exposure at the recommended daily dose.
Studies in pregnant rats showed that lamivudine is transferred to the fetus through the placenta. In the fertility/pre-and postnatal development study in rats, lamivudine was administered orally at doses of 180, 900, and 4,000 mg per kg per day (from prior to mating through postnatal Day 20). In the study, development of the offspring, including fertility and reproductive performance, was not affected by maternal administration of lamivudine.
Zidovudine: A study in pregnant rats (at 50, 150, or 450 mg per kg per day starting 26 days prior to mating through gestation to postnatal Day 21) showed increased fetal resorptions at doses that produced systemic exposures (AUC) approximately 33 times higher than exposure at the recommended daily human dose (300 mg twice daily). However, in an oral embryo-fetal development study in rats (at 125, 250, or 500 mg per kg per day on gestation Days 6 through 15), no fetal resorptions were observed at doses that produced systemic exposure (AUC) approximately 117 times higher than exposures at the recommended daily human dose.
An oral embryo-fetal development study in rabbits (at 75, 150, or 500 mg per kg per day on gestation Days 6 through 18) showed increased fetal resorptions at the 500 mg-per-kg-per-day dose, which produced systemic exposures (AUC) approximately 108 times higher than exposure at the recommended daily human dose; however, no fetal resorptions were noted at doses up to 150 mg per kg per day, which produced systemic exposure (AUC) approximately 23 times higher than exposures at the recommended daily human dose. These oral embryo-fetal development studies in the rat and rabbit revealed no evidence of fetal malformations with zidovudine.
In another developmental toxicity study, pregnant rats (dosed at 3,000 mg per kg per day from Days 6 through 15 of gestation) showed marked maternal toxicity and an increased incidence of fetal malformations at exposures greater than 300 times the recommended daily human dose based on AUC. However, there were no signs of fetal malformations at doses up to 600 mg per kg per day.
Breastfeeding considerations
Lactation (US label) US FDA label
8.2 Lactation Risk Summary The Centers for Disease Control and Prevention recommends that HIV‑1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV‑1 infection. Lamivudine and zidovudine are present in human milk. There is no information on the effects of lamivudine or zidovudine on the breastfed infant or the effects of the drugs on milk production.
Because of the potential for (1) HIV‑1 transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive infants), and (3) adverse reactions in a breastfed infant similar to those seen in adults, instruct mothers not to breastfeed if they are receiving COMBIVIR.
Mechanism of action
12.1 Mechanism of Action COMBIVIR is an antiretroviral agent [see Microbiology (12.4)].
US FDA labelPharmacokinetics
Urinary recovery of zidovudine and GZDV accounts for 14% and 74% of the dose following oral administration, respectively.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Pharmacokinetics in Adults One COMBIVIR tablet was bioequivalent to 1 EPIVIR tablet (150 mg) plus 1 RETROVIR tablet (300 mg) following single‑dose administration to fasting healthy subjects (n = 24). Lamivudine: Following oral administration, lamivudine is rapidly absorbed and extensively distributed.
Binding to plasma protein is low. Approximately 70% of an intravenous dose of lamivudine is recovered as unchanged drug in the urine. Metabolism of lamivudine is a minor route of elimination (approximately 5% of an oral dose after 12 hours). In humans, the only known metabolite is the trans‑sulfoxide metabolite (approximately 5% of an oral dose after 12 hours).
Zidovudine: Following oral administration, zidovudine is rapidly absorbed and extensively distributed. Binding to plasma protein is low. Zidovudine is eliminated primarily by hepatic metabolism. The major metabolite of zidovudine is GZDV. GZDV area under the curve (AUC) is about 3‑fold greater than the zidovudine AUC. Urinary recovery of zidovudine and GZDV accounts for 14% and 74% of the dose following oral administration, respectively.
A second metabolite, 3′-amino-3′-deoxythymidine (AMT), has been identified in plasma. The AMT AUC was one-fifth of the zidovudine AUC. In humans, lamivudine and zidovudine are not significantly metabolized by cytochrome P450 enzymes. The pharmacokinetic properties of lamivudine and zidovudine in fasting subjects are summarized in Table 3.
Table 3. Pharmacokinetic Parameters a for Lamivudine and Zidovudine in Adults Parameter Lamivudine Zidovudine Oral bioavailability (%) 86 ± 16 n = 12 64 ± 10 n = 5 Apparent volume of distribution (L/kg) 1.3 ± 0.4 n = 20 1.6 ± 0.6 n = 8 Plasma protein binding (%) <36 <38 CSF:plasma ratio b 0.12 [0.04 to 0.47] n = 38 c 0.60 [0.04 to 2.62] n = 39 d Systemic clearance (L/h/kg) 0.33 ± 0.06 n = 20 1.6 ± 0.6 n = 6 Renal clearance (L/h/kg) 0.22 ± 0.06 n = 20 0.34 ± 0.05 n = 9 Elimination half-life (h) e 5 to 7 0.5 to 3 a Data presented as mean ± standard deviation except where noted. b Median [range]. c Children. d Adults. e Approximate range.
Effect of Food on Absorption of COMBIVIR: COMBIVIR may be administered with or without food. The lamivudine and zidovudine AUC following administration of COMBIVIR with food was similar when compared with fasting healthy subjects (n = 24). Specific Populations Patients with Renal Impairment: COMBIVIR: The effect of renal impairment on the combination of lamivudine and zidovudine has not been evaluated (see the U.S. prescribing information for the individual lamivudine and zidovudine components).
Patients with Hepatic Impairment: COMBIVIR: The effect of hepatic impairment on the combination of lamivudine, and zidovudine has not been evaluated (see the U.S. prescribing information for the individual lamivudine and zidovudine components). Pregnant Women: Lamivudine: Lamivudine pharmacokinetics were studied in 36 pregnant women during 2 clinical trials conducted in South Africa.
Lamivudine pharmacokinetics in pregnant women were similar to those seen in non-pregnant adults and in postpartum women. Lamivudine concentrations were generally similar in maternal, neonatal, and umbilical cord serum samples. Zidovudine: Zidovudine pharmacokinetics have been studied in a Phase 1 trial of 8 women during the last trimester of pregnancy.
Zidovudine pharmacokinetics were similar to those of non-pregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery. Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics.
Geriatric Patients: The pharmacokinetics of lamivudine and zidovudine have not been studied in subjects over 65 years of age. Male and Female Patients: There are no significant or clinically relevant gender differences in the pharmacokinetics of the individual components (lamivudine or zidovudine) based on the available information that was analyzed for each of the individual components.
Racial Groups: Lamivudine: There are no significant or clinically relevant racial differences in lamivudine pharmacokinetics based on the available information that was analyzed for the individual lamivudine component. Zidovudine: The pharmacokinetics of zidovudine with respect to race have not been determined. Drug Interaction Studies No drug interaction trials have been conducted using COMBIVIR tablets.
Lamivudine and Zidovudine: No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed in 12 asymptomatic HIV‑1-infected adult subjects given a single dose of zidovudine (200 mg) in combination with multiple doses of lamivudine (300 mg every 12 hours). Interferon Alfa: There was no significant pharmacokinetic interaction between lamivudine and interferon alfa in a trial of 19 healthy male subjects.
Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV‑1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV‑1/HCV co‑infected subjects.
Sorbitol (Excipient): Lamivudine and sorbitol solutions were coadministered to 16 healthy adult subjects in an open-label, randomized-sequence, 4-period, crossover trial. Each subject received a single 300-mg dose of lamivudine oral solution alone or coadministered with a single dose of 3.2 grams, 10.2 grams, or 13.4 grams of sorbitol in solution.
Coadministration of lamivudine with sorbitol resulted in dose-dependent decreases of 20%, 39%, and 44% in the AUC (0-24); 14%, 32%, and 36% in the AUC (∞); and 28%, 52%, and 55% in the C max: of lamivudine, respectively. Table 4 presents drug interaction information for the individual components of COMBIVIR. Table 4. Effect of Coadministered Drugs on Lamivudine and Zidovudine AUC a Coadministered Drug and Dose Drug and Dose n Concentrations of Lamivudine or Zidovudine Concentration of Coadministered Drug AUC Variability Nelfinavir 750 mg every 8 h x 7 to 10 days Lamivudine single 150 mg 11 ↑10% 95% CI: 1% to 20% ↔ Trimethoprim 160 mg/ Sulfamethoxazole 800 mg daily x 5 days Lamivudine single 300 mg 14 ↑43% 90% CI: 32% to 55% ↔ Atovaquone 750 mg every 12 h with food Zidovudine 200 mg every 8 h 14 ↑31% Range: 23% to 78% b ↔ Clarithromycin 500 mg twice daily Zidovudine 100 mg every 4 h x 7 days 4 ↓12% Range: ↓34% to ↑14% Not Reported Fluconazole 400 mg daily Zidovudine 200 mg every 8 h 12 ↑74% 95% CI: 54% to 98% Not Reported Methadone 30 to 90 mg daily Zidovudine 200 mg every 4 h 9 ↑43% Range: 16% to 64% b ↔ Nelfinavir 750 mg every 8 h x 7 to 10 days Zidovudine single 200 mg 11 ↓35% Range: 28% to 41% ↔ Probenecid 500 mg every 6 h x 2 days Zidovudine 2 mg/kg every 8 h x 3 days 3 ↑106% Range: 100% to 170% b Not Assessed Rifampin 600 mg daily x 14 days Zidovudine 200 mg every 8 h x 14 days 8 ↓47% 90% CI: 41% to 53% Not Assessed Ritonavir 300 mg every 6 h x 4 days Zidovudine 200 mg every 8 h x 4 days 9 ↓25% 95% CI: 15% to 34% ↔ Valproic acid 250 mg or 500 mg every 8 h x 4 days Zidovudine 100 mg every 8 h x 4 days 6 ↑80% Range: 64% to 130% b Not Assessed ↑ = Increase; ↓= Decrease; ↔ = No significant change; AUC = Area under the concentration versus time curve; CI = Confidence interval. a This table is not all inclusive. b Estimated range of percent difference.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Lamivudine + Zidovudine 150 mg + 300 mg tablet | ₱7.48 | per tablet | DPRI reference price |
Reference price based on the DOH Central Office Bids and Awards Committee procurement price 2020
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Lamivudine + Zidovudine; Zidovudine + Lamivudine |
| PNF listing | Oral: 150 mg + 300 mg tablet |
| PNF listing | Oral: 60 mg + 30 mg dispersible tablet |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. COMBIVIR · ViiV Healthcare Company [US FDA-approved label, version 22, August 22, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16da660b-9981-4d24-a14a-94c7744fce4f
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .